FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

House Oversight Panel Probes Drug Shortages

The House Committee on Oversight and Accountability calls on FDA to provide extensive information on its response to a growing number of what the comm...

latest-news-card-1
Human Drugs

Supernus Parkinsons Off Episodes NDA Refiled

FDA accepts for review a Supernus Pharmaceuticals NDA resubmission for its apomorphine infusion device (SPN-830) for the continuous treatment of Parki...

latest-news-card-1
Federal Register

Guide on Clinical e-Thermometer

Federal Register notice: FDA makes available a final guidance entitled Enforcement Policy for Clinical Electronic Thermometers.

Medical Devices

Empatica Adds 2 Biomarkers to Monitoring Device

FDA clears an Empatica 510(k) for two new digital biomarkers for its Empatica Health Monitoring Platform pulse and respiratory rate.

latest-news-card-1
FDA General

House GOPers Concerned About FDA Lab Safety

Republican members of the House Energy and Commerce Committee express concern about FDA inaction on the safety of agency laboratory operations and the...

latest-news-card-1
Human Drugs

Hold on Nurix B-cell Malignancies Study

A transition to an improved manufacturing process leads to an FDA partial clinical hold on a Nurix Therapeutics clinical study evaluating NX-2127 in v...

latest-news-card-1
Federal Register

Patient Engagement Panel Renewal

Federal Register notice: FDA renews its Patient Engagement Advisory Committee for an additional two years beyond the charter expiration date.

latest-news-card-1
Human Drugs

Harvard Drug Group Recalls Eye Drops

The Harvard Drug Group recalls all lots of polyvinyl alcohol, 1.4% lubricating eye drops and lubricating tears eye drops (dextran/hypromellose, 0.1%/0...

latest-news-card-1
Biologics

FDA/Moderna Revolving Door Analyzed

A BMJ investigation looks at the case of two former FDA vaccine officials who now work for Moderna.

latest-news-card-1
Human Drugs

Lilly Sees Alzheimers Drug Decision Delay

Eli Lilly says that an FDA review decision for its experimental Alzheimers drug donanemab has been pushed back to the first quarter of 2024.